Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers

NCT04781322 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

NIH

Sponsor class

Conditions

Alcohol Associated Liver Disease
Heavy Drinking Behavior

Interventions

DRUG: Alirocumab
OTHER: Placebo

Sponsor

National Institute on Alcohol Abuse and Alcoholism (NIAAA)